Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
M & A Digital Health Innovation

23andMe Acquires Telehealth Company Lemonaid Health For $400M

  • News

Executive Summary

With the acquisition of Lemonaid Health, at-home genome testing company 23andMe hopes to transform the primary care business with genetics insights.

You may also be interested in...



Digital Health Roundup: Digital Therapeutics Push Ahead On Standards, Coverage; FDA’s Software Guidance

In this roundup feature focusing on developments in digital health, we highlight the key news and announcements from October.

Digital Health Start-Ups Continue To Be Attractive SPAC Targets

According to Rock Health, 52 health-care focused SPACs are looking for targets. This comes as blank check companies are facing rising scrutiny by regulators.

23AndMe To Go Public At $3.5Bn With Sir Richard Branson-Backed SPAC

23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.

Table

View full table

Topics

Related Companies

Tags:
M & A Digital Health Innovation
Latest Headlines

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says

Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

See All
UsernamePublicRestriction

Register

MT144628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By